up from here, page-17

Relenza had missed the pandemic stockpiling jackpot! GSK with or without the law suit is promoting GSK vaccine and we know what the "best endeavor" promotion of Relenza is.
However Science is on the good fortune side of Relenza with problems & virus resistance to Tamiflu. Relenza will increase the market share from Tamiflu but the bottom had fallen out of the pandemic stockpiling market as proven by Tamiflu sale results and Relenza sales in the last 2 quarters.

Lani is very promising BUT that is years and years away.


Let see what these facts reveal on the wonderful Biota Management.
The 2007 Final Accounts show $62 million : $39M kept as Cash in hand and in bank; $23M in deposit with average maturity rate of 30/90 days.

And the total interests earned is $2.498M for the year

182.711 M on 30/ Jun07 with 4.117M came from exercised employee options. On 1 Jul 07, there are 3.2M exercise-able employee options with an average contractual life of 3.35 years!

The Dec A/C shows in the 6 months the $62 M cash is reduced to $52M. The 182.711M shares increased to 183.335M all from employee shares options.

IF the shareholders sacked the management and ceased all activity, there will still be $62M in the bank account plus interest earned for 6 months.

It does not require rocket science to beat the $2.498M interests earned for the whole 06/07 financial year.

Judge the BTA management by the results. The sp trend is a good indicator of how great this management team is.